Annexon, Inc. Share Price
ANNXAnnexon, Inc. Stock Performance
Open $5.75 | Prev. Close $5.65 | Circuit Range N/A |
Day Range $5.63 - $5.93 | Year Range $1.29 - $7.16 | Volume 1,50,747 |
Average Traded $5.78 |
Annexon, Inc. Share Price Chart
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
16-Mar-26 | $5.75 | $5.75 | +0.00% |
16-Mar-26 | $5.75 | $5.75 | +1.41% |
13-Mar-26 | $5.70 | $5.67 | +4.04% |
12-Mar-26 | $5.79 | $5.45 | -9.47% |
11-Mar-26 | $6.18 | $6.02 | -1.31% |
10-Mar-26 | $5.80 | $6.10 | +8.73% |
09-Mar-26 | $5.07 | $5.61 | +8.72% |